News & Insights

Stay Informed With Our Latest Updates

Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.

Insights > Keyword
Insights > Type
Global > Practices
Global > Industries
Insights > Location
Insights > Person
Insights > Date Filter
3911 Results Found

Firm News August 15, 2025

Gibson Dunn Represents RTW Investments in Acquisition of Synthetic Royalty Interest in Anaphylm™

Gibson Dunn is representing RTW in its acquisition from Aquestive Therapeutics of a synthetic royalty interest in Anaphylm™ (epinephrine) Sublingual Film, and in its acquisition of Aquestive common stock as the lead investor in the company’s $85 million underwritten offering

Firm News July 3, 2025

Gibson Dunn Represented HealthCare Royalty and Blue Owl Capital in Acquisition of BridgeBio Pharma’s Royalty Interest in Bayer’s BEYONTTRA®

Gibson Dunn advised HealthCare Royalty and Blue Owl Capital on their acquisition from BridgeBio Pharma of its royalty interest in Bayer’s BEYONTTRA® for $300 million.